Abstract A88: Safety, pharmacokinetic, and pharmacodynamic results of BAY 86–9766, an oral MEK inhibitor, in combination with sorafenib, an oral multikinase inhibitor, in advanced cancer patients
Adjei, Alex A., Richards, Donald A., El-Khoueiry, Anthony, Becerra, Carlos H.R., Stephenson, Joe J., Leffingwell, Diane P., Iverson, Cory, Miner, Jeffrey N., Shen, Zancong, Gunawan, Sonny, Wilson, David, Manhard, Kimberly J., Dubowy, Ron L., Jeffers, Michael, Rajagopalan, Prabhu, Franklin, Wilbur A., Haney, Jerry, Lenhart, Patricia, Clendeninn, Neil J.
Published in Molecular cancer therapeutics (12.11.2011)
Published in Molecular cancer therapeutics (12.11.2011)
Get full text
Journal Article